MegaTAL
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology
Actionable Insights Powered by AI
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology